HETEROARYLALKYL-8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS
    62.
    发明申请
    HETEROARYLALKYL-8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS 有权
    异噻唑啉-8-氨基胆碱[3.2.1] OCT化合物作为阿片受体拮抗剂

    公开(公告)号:US20100152199A1

    公开(公告)日:2010-06-17

    申请号:US12703931

    申请日:2010-02-11

    IPC分类号: A61K31/46 A61K31/496 A61P1/00

    CPC分类号: C07D451/02

    摘要: The invention provides heteroarylene substituted 8-azabicyclo[3.2.1]octane compounds of formula (I): wherein R1, R2, A, and m are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.

    摘要翻译: 本发明提供式(I)的亚杂芳基取代的8-氮杂双环[3.2.1]辛烷化合物:其中R1,R2,A和m在说明书中定义,或其药学上可接受的盐,其为在mu 阿片受体。 本发明还提供包含这些化合物的药物组合物,使用这些化合物治疗与阿片样物质受体活性相关的病症的方法,以及可用于制备这些化合物的方法和中间体。

    Disubstituted alkyl-8-azabicyclo[3.2.1] octane compounds as mu opioid receptor antagonists
    67.
    发明申请
    Disubstituted alkyl-8-azabicyclo[3.2.1] octane compounds as mu opioid receptor antagonists 有权
    二取代的烷基-8-氮杂双环[3.2.1]辛烷化合物作为μ阿片受体拮抗剂

    公开(公告)号:US20090062332A1

    公开(公告)日:2009-03-05

    申请号:US12229636

    申请日:2008-08-26

    IPC分类号: C07D451/02 A61K31/46 A61P1/00

    CPC分类号: C07D451/02

    摘要: The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.

    摘要翻译: 本发明提供了式(I)的新的8-氮杂双环[3.2.1]辛烷化合物:其中变量在说明书中定义,或其药学上可接受的盐,它们是μ阿片受体的拮抗剂。 本发明还提供包含这些化合物的药物组合物,使用这些化合物治疗与阿片样物质受体活性相关的病症的方法,以及可用于制备这些化合物的方法和中间体。